NCT02213718

The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 40 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study is to assess the effect of desflurane on myocardial function in patents who underwent coronary artery bypass grafting.

Detailed description

Desflurane, one of the third-generation inhaled anesthetics, is introduced in clinical practice in 1990s. Decades of clinical use has provided evidence for desflurane's safe and efficacious use as a general anesthetic. Compared with other volatile anesthestics, it has several characteristics: lower blood and lipid solubility, more stable in vitro and the lowest in vivo metabolism. Its particular low fat solubility properties promote rapid equilibration and rapid elimination at the end of anesthesia which reduces slow compartment accumulation and promotes predictable emergence, early extubation, and the ability to rapidly transfer patients from the operating room to the recovery unit. In addition, several investigations found that patients with desflurane anesthesia recovered their protective airway reflexes and awakened to a degree sufficient to minimize the stay in the high dependency recovery area. A burgeoning body of investigations has shown that desflurane can directly act on myocardial and vascular functions. Desflurane has coronary vasodilative effects in in situ canine hearts which is comparable to sevoflurane does. Although it is controversial regarding to the effect of desflurane on myocardial excitation-contraction coupling and electrophysiologic behavior, a elaborated study found desflurane induced a positive inotropic effect in rat myocardium in vitro compared with isoflurane. A recent study suggested that desflurane decreased right ventricular contractility much less and maintained the right over left pressures ratio at more favorable values compared with sevoflurane. Furthermore, substantial investigations found that clinically relevant concentration desflurane preconditioning or postconditioning could protect myocardium from ischemia-reperfusion in mammalian animal models or isolated human cardiac tissues. However, it is unclear whether desflurane can provide protection for patients with coronary artery disease. Therefore, this study is designed to investigate the effect of desflurane on myocardial function in patents who underwent coronary artery bypass grafting.

Conditions

• Coronary Artery Bypass Graft Redo
• General Anesthetic Drug Adverse Reaction

Interventions

Type	Name	Description
DRUG	Desflurane	desflurane (7%-8% end-tidal concentration)
DRUG	propofol	propofol (TCI:3.5-4.0μg/min)
DRUG	sufentanil	TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours

Timeline

• Start date: 2014-07-01
• Primary completion: 2017-01-01
• Completion: 2017-06-01
• First posted: 2014-08-11
• Last updated: 2014-08-11

Locations

1 site across 1 country: China